又一女将带队，成都明星公司要IPO了

Core Viewpoint - The article highlights the increasing trend of female entrepreneurs pursuing IPOs, with a focus on the success of Zaling Bio, led by Chen Lijuan, and other notable companies in the same wave [3][5][15]. Company Overview - Zaling Bio, founded in 2019 by Chen Lijuan, emerged from the technology transfer initiatives of Sichuan University West China Hospital, aiming to bridge the gap between laboratory research and clinical application of innovative drugs [7][8]. - The company focuses on small molecule therapies for blood system diseases, tumors, central nervous system diseases, and immune/inflammatory diseases, with products like FM and PM in various clinical trial stages [8][10]. Financial Performance - Zaling Bio has raised over 1.1 billion yuan in funding, with significant investments from various venture capital firms, including Tencent and Qiming Venture Partners [10][12]. - Despite ongoing R&D investments exceeding 160 million yuan, the company reported a net loss of over 91 million yuan in 2024 and nearly 120 million yuan in the first nine months of 2025 [8][10]. Investment and Valuation - The company's valuation has surpassed 3.4 billion yuan following multiple funding rounds, with notable investors recognizing the differentiated drug design and promising clinical data [9][12][14]. - Chen Lijuan holds approximately 25.6% voting rights in the company, translating to a personal valuation of several hundred million yuan based on the latest funding round [14]. Industry Trends - The article notes a surge in female-led companies seeking IPOs, with examples including Qian Dama, Yinuo Medical, and Wenstone Information, all of which have made significant strides in their respective fields [15][17]. - The trend reflects a broader societal shift towards recognizing and supporting female entrepreneurs, contributing to a growing number of successful IPOs in various industries [15][17].